New York, Nov 4 (AP) Moderna is scaling back expectations for the number of COVID-19 vaccine deliveries it expects to make this year and the revenue it will record from them.

The drugmaker said Thursday that longer delivery lead times for exports and a temporary impact from expanding its fill-finish capacity may shift some deliveries to early 2022.

Also Read | Diwali 2021: UK Minister Rishi Sunak Releases New 5-Pound Gandhi Commemorative Coin to Mark Festival of Lights.

The company now expects full-year, 2021 product sales of between $15 billion and $18 billion.

That's down from a prediction for $20 billion in sales that it made in August.

Also Read | Los Angeles Mayor Eric Garcetti, US' Next Ambassador to India, Tests COVID-19 Positive in Glasgow.

Moderna's COVID-19 vaccine is the only product the drugmaker has on the market. It brought in $4.81 billion in sales during the third quarter, up from $4.2 billion the previous quarter.

The Cambridge, Massachusetts, company also reported on Thursday third-quarter results that missed expectations.

Company shares fell almost 11% before the opening bell.

Moderna Inc. makes one of three COVID-19 vaccines currently being used in the United States.

The others are made by Pfizer Inc. and Johnson & Johnson. (AP) VM

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)